Egis in the World

Our products reach 100 countries

Click here to learn more

Pharmaceutical Company

Our activities incorporate all areas in the pharmaceutical value chain

Click here to learn more

Research & Development

One of the fundamental pillars of our strategy is innovation. We devoted EUR 48 million to research and development in the 2022/2023 financial year.

Click here to learn more
Egis World Pharmaceutical Company R&D
Own subsidiaries / Representative offices
Sales through Partners
Egis World

Egis' medicines won the Innovation Grand Prize

Two of Egis’ fixed-dose combination drugs have won the Innovation Grand Prize. The awarded Egis medicines feature significant innovations as they reduce the risk of cardiovascular events related to atherosclerosis due to the combined lipid-lowering therapy. In respect of these two products the company obtained three patents related to active ingredient development and two patents related to formulation development that are all relevant to large-scale manufacturing technologies. The recognition was not without a history, as this is the tenth time an Egis medicine has received an Innovation Prize or Grand Prize.

More
Egis World

Csaba Poroszlai is CEO of Egis Pharmaceuticals PLC

Csaba Poroszlai is confirmed CEO of the company by the Board of Directors of Egis. Balázs Vándor is appointed to the position of the Company’s Chief Financial Officer.

More
Health

A Decade-Long Commitment to the Treatment of Cancer

We have commemorated World Cancer Day.

More
More articles

Egis in the World

Egis’ products reach 100 countries around the world.

Egis’ products reach 100 countries. Our portfolio consists of 653 products.  Our main focus lies on treating diseases of the cardiovascular and central nervous systems.

Learn more

A place to work

Join us!

Learn more

Healthcare Professionals

and prescription drugs

Professional content for visitors with qualification in medicine or pharmaceuticals These contents are available with password protection - please contact our representative or require your own account at the Contact menu.

Learn more
Terapeutické oblasti
Terapeutické oblasti
Allergology
Anti inflammatory
Cardiovascular system
Central nervous system
Diabetology
Gastroenterology
Oncology
Urology
Women´s health

Gallery

Downloads

Our related products

More
Quick news
Jan 31.

Part of Gyógyszergyári Street Renamed after István Orbán

On 29 January, based on the unanimous decision of the General Assembly of Budapest, a part of Kőbánya’s (10th District of Budapest) Gyógyszergyári Street was renamed and from now on pays tribute to our beloved former CEO, István Orbán.
More
Jun 14.

Three Egis Subsidiaries Among the Best Employers

Following the success of Egis Russia and Egis Polska, we are proud to announce that Egis Praha has also been recognized as Best Employer at Aon Hewitt’s Employee Engagement Survey.
More
Jun 13.

Egis strengthens European presence in the biosimilar area

Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections.
More
Jun 10.

Egis Russia Wins Prestigious Award for CSR Campaign

Egis Russia’s Buy for Good campaign that was carried out in 2018 won the award of ‘Best Social Projects in Russia’ in the category of medical and social projects.
More
Apr 24.

When creative minds meet

One of the pillars of our corporate culture is innovation. We do not only talk about it, but enjusre the flow of ideas with annual forums that offer space for making proposals in connection with scientific research, manufacturing, how to make our administrative process more effective and the latest item on our agenda: digitalization.
More
Apr 09.

A Journey to the Empire of Health

This March, the Hungarian Nationwide Public Health Screening Program’s special campaign sets off to teach children about health maintenance and prevention measures.
More

Safety and quality

If you suspect an adverse reaction related to the use of EGIS, or a suspected quality problem or counterfeit, please contact:

GO TO FORM
Play video
Show gallery
flag
No. of employees
No. of products
Subsidiary/representation was established in
flag
No. of employees
No. of products
Subsidiary/representation was established in

Play video
Show gallery

Play video

Gallery

Downloads

Our related products

Cookie Settings

Egis’s website uses cookies to run our website, improve the user experience and monitor the activities. You can customize the use of the cookies by adapting the settings.

Cookies necessary for basic functioning

These cookies ensure the appropriate functioning of the website, facilitate its use and collect information on its use without identifying visitors.

Functional cookies

In order to enhance the user experience, we use cookies which record the use of certain functions of the website, thus enabling users to have the same settings at the time of their next visit.

Cookies for statistical purposes

They provide statistical data on the performance of the website (such as number of page loads, average time spent on the website) in order to collect data for the operator of the website on the website usage patterns of users. These cookies do not identify visitors, information collected by them relate to the number of subpages visited by the user, the length of each session, the types of error messages, etc. Cookies for statistical purposes are automatically placed on the user’s devices during browsing, and you can delete such cookies in the browser settings.
Details
I Agree
WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox